{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Amplification&page=5", "query": { "condition": "Amplification", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 148, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Amplification&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Amplification&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T04:15:17.415Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06915753", "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Solid Tumors", "Solid Tumor, Adult", "FGFR Gene Amplification", "FGFR Gene Alterations", "Advanced Solid Tumors", "FGFR4 Gene Mutation", "FGFR4 Gene Fusions", "FGF19 Gene Amplification", "FGF19 Gene Overexpression", "Locally Advanced Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "TYRA-430", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2025-04-24", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06915753" }, { "nct_id": "NCT04879121", "title": "Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Larotrectinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 13, "start_date": "2021-04-30", "completion_date": "2027-11-11", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879121" }, { "nct_id": "NCT05873686", "title": "A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "NSCLC (Non-small Cell Lung Cancer)", "Renal Cancer", "Mesothelioma", "Non-Small Cell Squamous Lung Cancer", "Non-small Cell Lung Adenocarcinoma" ], "interventions": [ { "name": "NXP900", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvectis Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2023-10-26", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 13, "location_summary": "Phoenix, Arizona • La Jolla, California • Denver, Colorado + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05873686" }, { "nct_id": "NCT05029882", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Advanced Solid Tumors", "Gastroesophageal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Trifluridine/Tipiracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2021-10-13", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 18, "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05029882" }, { "nct_id": "NCT06136897", "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-03-23", "completion_date": "2027-01-15", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136897" }, { "nct_id": "NCT07361562", "title": "A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor, Adult", "ERBB2 Altered Breast Cancer", "ERBB2 Gene Amplification", "HER2 Overexpression", "Non-Small Cell Lung Cancer", "HER2" ], "interventions": [ { "name": "CGT4255", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-12-30", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07361562" }, { "nct_id": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER-2 Gene Amplification", "Esophagus Cancer", "Gastroesophageal Junction Cancer", "Stomach Cancer" ], "interventions": [ { "name": "MM-111", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2013-01", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-06-22", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01774851" }, { "nct_id": "NCT04292119", "title": "Lorlatinib Combinations in Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Anaplastic Lymphoma Kinase Gene Translocation", "ROS1 Rearrangement", "Relapsed Cancer", "MET Amplification", "Resistant Cancer", "NSCLC" ], "interventions": [ { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2020-05-01", "completion_date": "2023-03-01", "has_results": false, "last_update_posted_date": "2021-03-10", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04292119" }, { "nct_id": "NCT03410927", "title": "A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors With HER2 Abnormalities", "Advanced Solid Tumors With HER3 Abnormalities" ], "interventions": [ { "name": "TAS0728", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2018-04-06", "completion_date": "2022-06-09", "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 5, "location_summary": "Duarte, California • Atlanta, Georgia • New York, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03410927" }, { "nct_id": "NCT01066507", "title": "Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Applied Spectral Imaging Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 126, "start_date": "2008-07", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2010-02-10", "last_synced_at": "2026-10-23T04:15:17.415Z", "location_count": 2, "location_summary": "Lakewood, New Jersey • Temple, Texas", "locations": [ { "city": "Lakewood", "state": "New Jersey" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01066507" } ] }